Last reviewed · How we verify
NCT07118735: NCKUH
AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy
NA trial testing A standardized extract of cultured Lentinula edodes mycelia (AHCC®) in Liver Cancer in 94 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | National Cheng-Kung University Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 94 |
| Start date | 20 August 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- A standardized extract of cultured Lentinula edodes mycelia (AHCC®)
- Placebo
Conditions studied
- Liver Cancer — all drugs for Liver Cancer →
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
National Cheng-Kung University Hospital
Who can join
20 and older, any sex, with Liver Cancer or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC® (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07118735
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cancer
Currently open trials in the same condition.
- NCT07295275 — Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07295340 — Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection · recruiting
- NCT07504367 — Large Language Models Assist in Tumor MDT · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
Other National Cheng-Kung University Hospital trials
Trials by the same sponsor.
- NCT07525713 — Virtual Reality Mirror Therapy With Focused Object-Directed Attention System · NA · not yet recruiting
- NCT07369271 — Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery · NA · not yet recruiting
- NCT07262411 — Peer-based Recovery Program · NA · not yet recruiting
- NCT07257926 — Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Contr · Phase 4 · not yet recruiting
- NCT07269132 — Applying the ADDIE Model to Develop a Multimedia Program to Enhance Chemotherapy Knowledge and Self-Efficacy Among Inten · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07118735 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cheng-Kung University Hospital
- Last refreshed: 12 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07118735.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing